Evidence map›Paper›PMID 32867698›Full record

Trial reportBMC infectious diseases2020

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines.

Siyue Jia, Rong Tang, Guifan Li, Yuemei Hu, Qi Liang

3 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03902054 phase2completednot on this map

A Randomized, Blinded and Controlled Phase II Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell) in Infants.

TypeinterventionalSponsorJiangsu Province Centers for Disease Control and PreventionRan2017 to 2018Enrolled600ConditionsPolio and Post-Polio SyndromeArmsThree-dose regimen of high dosage investigational sIPV, Three-dose regimen of medium dosage investigational sIPV, Three-dose regimen of low dosage investigational sIPV, Three-dose regimen of commercialized sIPV, Three-dose regimen of commercialized IPV
NCT04264546 phase1 / phase2completednot on this map

A Phase Ib Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell)

TypeinterventionalSponsorJiangsu Province Centers for Disease Control and PreventionRan2017 to 2018Enrolled60ConditionsPolioArmssIPV
NCT04264598 phase1completednot on this map

A Phase I Study to Evaluate the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Vero Cell)

TypeinterventionalSponsorJiangsu Province Centers for Disease Control and PreventionRan2017 to 2018Enrolled100ConditionsPolioArmssIPV, Commercialized sIPV, Commercialized IPV
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Relationship BetweenFrontiers in medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Siyue JiaJiangsu Provincial Center for Disease Control and Prevention, NO. 172 Jiangsu Rd., Gulou District, Nanjing, 210009, Jiangsu Province, China.
Rong TangJiangsu Provincial Center for Disease Control and Prevention, NO. 172 Jiangsu Rd., Gulou District, Nanjing, 210009, Jiangsu Province, China.
Guifan LiBeijing Minhai Biotechnology Co. Ltd., Beijing, China.
Yuemei HuJiangsu Provincial Center for Disease Control and Prevention, NO. 172 Jiangsu Rd., Gulou District, Nanjing, 210009, Jiangsu Province, China.
Qi LiangJiangsu Provincial Center for Disease Control and Prevention, NO. 172 Jiangsu Rd., Gulou District, Nanjing, 210009, Jiangsu Province, China. jscdclq@126.com.
Jiangsu Provincial Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMaternal poliovirus antibodies could provide passive immunity to the newborns from poliovirus infection during their first few months of life, but they may impair the immune responses of infants to the poliovirus vaccine as well. In our study, we pooled the data from three clinical trials of the inactivated poliovirus vaccine (IPV) based on Sabin strains to investigate the effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines.

methodsThere were five groups in the pooled analysis, including low-dose Sabin IPV, medium-dose Sabin IPV, high-dose Sabin IPV, control Sabin IPV, and control Salk IPV groups. We reclassified the infants in different groups according to their maternal poliovirus antibodies by two methods, the first one included maternal antibody negative (< 1:8) and maternal antibody positive (≥1:8), and the second one included maternal antibody titer < 1:8, 1:8 ~ < 1:32 and ≥ 1:32. Then, we compared the geometric mean titers (GMTs), geometric mean antibody fold increases (GMIs) and seroconversion rates of poliovirus type-specific neutralizing antibodies after vaccination among participants with different maternal poliovirus antibody levels.

resultsThe GMTs and GMIs of three types of poliovirus antibodies after vaccination in maternal antibody negative participants were significantly higher than those in maternal antibody positive participants. The seroconversion rates of type II and type III poliovirus antibodies in maternal antibody positive participants were significantly lower than those in maternal antibody negative participants. Among participants with maternal antibody titer < 1:8, 1:8 ~ < 1:32 and ≥ 1:32, the GMTs and GMIs of three types of poliovirus antibodies after vaccination showed a tendency to decline with the increasing of maternal antibody levels. The seroconversion rates of three types of poliovirus antibodies in participants with maternal antibody titer ≥1:32 were significantly lower than those in participants with maternal antibody titer < 1:8 and 1:8 ~ < 1:32.

conclusionsMaternal poliovirus antibodies interfered with the immune responses of infants to poliovirus vaccines, and a high level of maternal antibodies exhibited a greater dampening effect.

trial registrationClinicalTrials.gov NCT04264598 February 11, 2020; ClinicalTrials.gov NCT04264546 February 11, 2020; ClinicalTrials.gov NCT03902054 April 3, 2019. Retrospectively registered.

Indexed as

Immunogenicity, VaccineAntibodies, NeutralizingAntibodies, ViralChinaFemaleHumansImmunity, Maternally-AcquiredInfantMalePoliomyelitisPoliovirusPoliovirus Vaccine, InactivatedSeroconversionVaccinationAntibodies, NeutralizingAntibodies, ViralPoliovirus Vaccine, InactivatedImmune responseMaternal antibodyPoliovirus vaccine

Identifiers

PMID32867698
PMCPMC7460787
OpenAlexW3081541933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.